PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AZ, Pfizer/BioNTech vaccines ‘highly effective’ against Delta variant

AstraZeneca and Pfizer/BioNTech’s COVID-19 vaccines are ‘highly effective’ at protecting against the Delta (previously known as the Indian) variant, according to new real-world data from Public Health England (PHE).
The analysis included 14,019 cases of the Delta variant, of which 166 were hospitalised, between 12 April and 4 June, looking at emergency hospital admissions in England.
The new data, published as a pre-print, demonstrated that two doses of AZ’s COVID-19 vaccine are 92% effective against hospitalisation caused by the Delta variant, with no deaths observed among vaccinated individuals.
The data also showed the vaccine had high levels of effectiveness against the Alpha variant – first identified in the UK – with an 86% reduction of hospitalisations and no deaths reported.
However, the data also showed that the vaccine is less effective against milder symptomatic COVID-19 disease.
The vaccine was 74% effective against symptomatic disease caused by the Alpha variant and 64% effective against the Delta variant.
Meanwhile, the Pfizer/BioNTech vaccine was found to be 96% effective against the Delta variant after two doses.
“It is extremely encouraging to see today’s research showing that vaccines are continuing to help break the link between hospitalisation and the Delta variant after one dose, and particularly the high effectiveness of two doses,” said Vaccines Minister Nadhim Zahawi.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026